Free Trial
NYSE:BLCO

Bausch + Lomb (BLCO) Stock Price, News & Analysis

$15.81
+0.28 (+1.80%)
(As of 07/26/2024 ET)
Today's Range
$15.36
$15.81
50-Day Range
$14.51
$17.30
52-Week Range
$13.16
$20.30
Volume
416,380 shs
Average Volume
496,080 shs
Market Capitalization
$5.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.95

Bausch + Lomb MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.58 Rating Score
Upside/​Downside
19.9% Upside
$18.95 Price Target
Short Interest
Healthy
5.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.15mentions of Bausch + Lomb in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
38.10%
From $0.63 to $0.87 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.86 out of 5 stars

Medical Sector

437th out of 936 stocks

Ophthalmic Goods Industry

4th out of 7 stocks

BLCO stock logo

About Bausch + Lomb Stock (NYSE:BLCO)

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

BLCO Stock Price History

BLCO Stock News Headlines

2 Red Alerts On Bausch Health Companies
How a $0.25 cent option contract makes my top traders feel
If you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…
Bausch + Lomb (BLCO) to Release Quarterly Earnings on Wednesday
Bausch Health Cos. Inc.
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
See More Headlines
Receive BLCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/01/2024
Today
7/26/2024
Next Earnings (Confirmed)
7/31/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
Medical Equipment
Fax
N/A
Employees
13,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.95
High Stock Price Target
$25.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+22.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.58
Research Coverage
12 Analysts

Profitability

Net Income
$-260,000,000.00
Pretax Margin
-4.66%

Debt

Sales & Book Value

Annual Sales
$4.15 billion
Cash Flow
$1.83 per share
Book Value
$19.72 per share

Miscellaneous

Free Float
N/A
Market Cap
$5.44 billion
Optionable
Optionable
Beta
0.47
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Osama A. Eldessouky (Age 52)
    Executive VP & CFO
    Comp: $1.09M
  • Dr. Yehia Hashad M.D. (Age 57)
    Executive VP of Research & Development and Chief Medical officer
    Comp: $1.09M
  • Mr. Brenton L. Saunders J.D. (Age 54)
    CEO & Chairman
  • Mr. Alan Waterhouse CPFA (Age 64)
    MBA, Executive VP and Chief Supply Chain & Operations Officer
  • Mr. Frederick J. Munsch (Age 53)
    Senior VP, Controller & Chief Accounting Officer
  • Mr. A. Robert D. Bailey (Age 61)
    Executive VP & Chief Legal Officer
  • Mr. Jonathon L. Kellerman
    Chief Compliance Officer
  • T.J. Crawford
    Chief Communications Officer
  • Dr. Manisha A. Narasimhan Ph.D. (Age 47)
    Chief Corporate Development & Digital Officer
  • Ms. Asli Gevgilili
    Executive VP & Chief Human Resources Officer

BLCO Stock Analysis - Frequently Asked Questions

How have BLCO shares performed this year?

Bausch + Lomb's stock was trading at $17.06 at the beginning of 2024. Since then, BLCO shares have decreased by 7.3% and is now trading at $15.81.
View the best growth stocks for 2024 here
.

How were Bausch + Lomb's earnings last quarter?

Bausch + Lomb Co. (NYSE:BLCO) released its quarterly earnings results on Wednesday, May, 1st. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.09 by $0.02. The business's quarterly revenue was up 18.0% on a year-over-year basis.

When did Bausch + Lomb IPO?

Bausch + Lomb (BLCO) raised $788 million in an initial public offering (IPO) on Friday, May 6th 2022. The company issued 35,000,000 shares at a price of $21.00-$24.00 per share.

Who are Bausch + Lomb's major shareholders?

Top institutional shareholders of Bausch + Lomb include Raymond James & Associates (0.06%), Renaissance Capital LLC (0.01%) and Blue Trust Inc..

How do I buy shares of Bausch + Lomb?

Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BLCO) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners